EUVIMEDEUVIMED entdecken
Crossref

Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction

Ji-Hun Jang, Seung-Hyun Jeong

Cancer Chemotherapy and Pharmacology · 20.05.2026 · 96 (1)

DOI: 10.1007/s00280-026-04900-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 20.05.2026. Verfasst von Ji-Hun Jang und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chonnam National University, 77 Yongbong-ro, Buk- gu, Gwangju, 61186, Republic of Korea. Hauptthemen laut MEDLINE: Granisetron, Antiemetics, Neoplasms, Models, Biological. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Granisetron, a selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, is widely used for the prevention and treatment of chemotherapy-induced nausea-vomiting in patients with cancer. However, quantitative data describing differences in in vivo pharmacokinetics (PK) among available formulations, including intravenous, oral, subcutaneous, and transdermal patches, and comparative drug concentrations at pharmacological target tissues, such as the central chemoreceptor trigger zone and enterovagal nerve terminals, remain limited. PURPOSE: This study aimed to develop a whole-body physiologically based pharmacokinetic (PBPK) model to predict systemic and pharmacological target tissue concentrations of granisetron across multiple routes of administration and to elucidate route-specific PK and target-tissue exposure characteristics to support optimization of antiemetic therapy. METHODS: A PBPK model was developed using literature-derived clinical PK data integrated with human physiological parameters and relevant in vitro data. The model was calibrated and validated against single-dose and multiple-dose clinical datasets. Predictive performance was evaluated using the ratio of model-predicted values ​​to observed values ​​and the proportion of observed data captured within prediction intervals. Subsequently, granisetron concentrations in pharmacological target tissues were simulated at clinically relevant doses for each route of administration. RESULTS: The PBPK model accurately reproduced plasma concentration-time profiles for all administration routes and demonstrated acceptable predictive accuracy for key PK parameters. Tissue-level simulations showed that intravenous and oral administration produced rapid and high central exposure, with oral administration reflecting rapid gastrointestinal absorption into the systemic circulation. In contrast, the transdermal patch provided sustained and stable central and peripheral exposure, whereas subcutaneous administration yielded prolonged systemic exposure compared with intravenous and oral dosing, resulting in intermediate systemic and target-tissue exposure. Distinct tissue exposure profiles and exposure durations were observed for each formulation. CONCLUSION: This study provides the first PBPK-based quantitative characterization of granisetron PK and target-tissue exposure across clinically relevant routes of administration. The findings support route-specific optimization of antiemetic therapy according to patient characteristics and clinical context. Furthermore, the developed model may facilitate personalized supportive care in oncology, including applications in vulnerable populations (e.g., older adults, individuals with hepatic impairment, pregnant patients), as well as formulation development research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GranisetronAntiemeticsNeoplasmsModels, BiologicalVomitingNauseaHumansAntineoplastic AgentsFemaleMaleAdultMiddle AgedAdministration, OralTissue Distribution

Stichwörter der Autor:innen

Chemotherapy-induced nausea and vomiting (CINV)GranisetronPhysiologically based pharmacokinetic (PBPK) modelingRoute-dependent drug deliveryTarget-site pharmacokinetics

Substanzen

GranisetronAntiemeticsAntineoplastic Agents

Autor:innen und Institutionen

  • College of Pharmacy, Chonnam National University, 77 Yongbong-ro, Buk- gu, Gwangju, 61186, Republic of Korea.
  • College of Pharmacy, Sunchon National University, 255 Jungang-ro, Suncheon-si, 57922, Jeollanam-do, Republic of Korea. jeongsh@scnu.ac.kr.
  • College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon-si, 57922, Republic of Korea. jeongsh@scnu.ac.kr.

Zitieren

APA

Jang, J. H., & Jeong, S. H. (2026). Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04900-1

Vancouver

Jang JH, Jeong SH. Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04900-1

BibTeX
@article{Jang2026,
  author = {Jang, Ji-Hun and Jeong, Seung-Hyun},
  title = {Physiologically based pharmacokinetic modeling of granisetron for optimizing antiemetic therapy in patients with cancer: multi-route pharmacokinetic characterization and target-site exposure prediction},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04900-1}
}
Kostenlos starten →